Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2110

1.

Ductal Carcinoma In Situ: The Whole Truth.

Parikh U, Chhor CM, Mercado CL.

AJR Am J Roentgenol. 2017 Oct 18:1-10. doi: 10.2214/AJR.17.18778. [Epub ahead of print]

PMID:
29045181
2.

Sentinel node biopsy in ductal carcinoma in situ of the breast: Never justified?

Sorrentino L, Sartani A, Bossi D, Amadori R, Nebuloni M, Truffi M, Bonzini M, Riggio E, Foschi D, Corsi F.

Breast J. 2017 Oct 11. doi: 10.1111/tbj.12928. [Epub ahead of print]

PMID:
29024241
3.

Fine needle aspiration of spindle cell ductal carcinoma <i>in situ</i> of the breast: A case report and the use of ancillary tests for the differential diagnosis of metaplastic carcinoma.

Chong Y, Lee YS, Kim TJ, Park WC, Kang CS, Lee EJ.

Cytojournal. 2017 Sep 25;14:23. doi: 10.4103/cytojournal.cytojournal_3_17. eCollection 2017.

4.

Application of a novel prognostic invasive lesion index in ductal carcinoma in situ with minimal invasion of the breast.

He X, Ye F, Li M, Yu P, Xiao X, Tang H, Xie X.

Cancer Med. 2017 Oct 4. doi: 10.1002/cam4.1175. [Epub ahead of print]

5.

Genomic Assays in Ductal Carcinoma In Situ: Implications for Management Decisions.

Gangi A, Topham A, Lee MC, Sun W, Laronga C.

South Med J. 2017 Oct;110(10):649-653. doi: 10.14423/SMJ.0000000000000712.

PMID:
28973706
6.

Invasive Micropapillary Carcinoma in Axillary Ectopic Breast and Synchronous Ductal Carcinoma <i>In Situ</i> in the Contralateral Breast.

Oh SW, Lim HS, Lee JS, Moon SM, Park MH.

J Breast Cancer. 2017 Sep;20(3):314-318. doi: 10.4048/jbc.2017.20.3.314. Epub 2017 Sep 22.

7.

Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.

Shurell E, Olcese C, Patil S, McCormick B, Van Zee KJ, Pilewskie ML.

Cancer. 2017 Sep 28. doi: 10.1002/cncr.30972. [Epub ahead of print]

PMID:
28960259
8.

Variable Appearances of Ductal Carcinoma In Situ Calcifications on Digital Mammography, Synthesized Mammography, and Tomosynthesis: A Pictorial Essay.

Hwang E, Szabo J, Sonnenblick EB, Margolies LR.

Can Assoc Radiol J. 2017 Sep 22. pii: S0846-5371(17)30058-X. doi: 10.1016/j.carj.2017.04.005. [Epub ahead of print] Review.

PMID:
28947267
9.

Trends in Treatment Patterns and Clinical Outcomes in Young Women Diagnosed With Ductal Carcinoma In Situ.

Park HL, Chang J, Lal G, Lal K, Ziogas A, Anton-Culver H.

Clin Breast Cancer. 2017 Aug 10. pii: S1526-8209(17)30258-6. doi: 10.1016/j.clbc.2017.08.001. [Epub ahead of print]

PMID:
28941977
10.

Margin width and local recurrence after breast conserving surgery for ductal carcinoma in situ.

Ekatah GE, Turnbull AK, Arthur LM, Thomas J, Dodds C, Dixon JM.

Eur J Surg Oncol. 2017 Sep 4. pii: S0748-7983(17)30637-6. doi: 10.1016/j.ejso.2017.08.003. [Epub ahead of print]

PMID:
28917445
11.

Ductal Carcinoma in Situ: Quantitative Preoperative Breast MR Imaging Features Associated with Recurrence after Treatment.

Luo J, Johnston BS, Kitsch AE, Hippe DS, Korde LA, Javid S, Lee JM, Peacock S, Lehman CD, Partridge SC, Rahbar H.

Radiology. 2017 Sep 14:170587. doi: 10.1148/radiol.2017170587. [Epub ahead of print]

PMID:
28914599
12.

Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?

Van Bockstal M, Libbrecht L, Floris G, Lambein K, Pinder S.

Ann Oncol. 2017 Sep 1;28(9):2317. doi: 10.1093/annonc/mdx253. No abstract available.

PMID:
28911076
13.

Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients.

Gregorowitsch ML, van den Bongard HJGD, Young-Afat DA, Pignol JP, van Gils CH, May AM, Verkooijen HM.

Breast Cancer Res Treat. 2017 Sep 11. doi: 10.1007/s10549-017-4495-y. [Epub ahead of print]

PMID:
28894982
14.

Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma <i>In Situ</i> of Breast.

Sagara Y, Julia W, Golshan M, Toi M.

Front Oncol. 2017 Aug 28;7:192. doi: 10.3389/fonc.2017.00192. eCollection 2017. Review.

15.

Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ.

Bosch DE, Kilgore MR, Schmidt RA, Swanson PE, Rendi MH, Chang OH.

Appl Immunohistochem Mol Morphol. 2017 Sep;25(8):543-547. doi: 10.1097/PAI.0000000000000555.

PMID:
28885232
18.

Detection of Ductal Carcinoma In Situ by Ultrasound and Mammography: Size-dependent Inaccuracy.

Eichler C, Abrar S, Puppe J, Arndt M, Ohlinger R, Hahn M, Warm M.

Anticancer Res. 2017 Sep;37(9):5065-5070.

PMID:
28870935
19.

Clinicopathological Features of Ductal Carcinoma In Situ from 18F-FDG-PET Findings.

Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Kuwano H.

Anticancer Res. 2017 Sep;37(9):5053-5056.

PMID:
28870933
20.

Radiation Therapy Following Breast Conserving Surgery for Ductal Carcinoma in situ: Yes or No?

Stoleru LS, Stoleru S.

Chirurgia (Bucur). 2017 Jul-Aug;112(4):403-412. doi: 10.21614/chirurgia.112.4.403.

Supplemental Content

Loading ...
Support Center